Pronova BioPharma Norge v. Teva Pharmaceuticals, No. 12-1498 (Fed. Cir. Sept. 12, 2013)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This patent infringement suit arises from Abbreviated New Drug Applications (“ANDAs”) filed by Teva Pharm a- ceuticals USA Inc. (“Teva”) and Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. (collectively “Par”) (with Teva, collectively “ Appellants”). Through their ANDAs, Appellants seek to market generic versions of Lovaza®, a pharmaceutical product marketed by Plai n- tiff Pronova BioPharma Norge AS (“Pronova”). Following a bench trial, the U.S.